论文部分内容阅读
目的定量检测晚期肺癌患者化疗过程中血浆RAS相关区域家族1A基因(RASSF1A)甲基化水平,探讨其在个体化治疗中的应用价值。方法采集24例晚期肺癌患者化疗前后静脉血共135份,用荧光定量甲基化特异性PCR(MSP)检测RASSF1A基因的甲基化水平,观察化疗前后的变化情况。结果 13例部分缓解组(partial remission,PR)患者化疗后甲基化定量水平明显升高(P<0.05),而11例未缓解组(stable disease,SD或progressive disease,PD)的患者化疗前后甲基化水平无明显变化;生存时间≥12个月的13例患者化疗后甲基化定量水平也明显升高(P<0.01),而生存时间<12个月的11例患者化疗前后甲基化水平无明显变化。生存曲线分析显示,化疗后有甲基化水平升高改变的患者总体生存时间更长(P<0.01)。结论晚期肺癌患者化疗前后血浆RASSF1A甲基化定量水平的检测,对评估化疗的疗效及预后有一定的价值,对个体化化疗的药物选择有一定的指导意义。
Objective To quantitatively detect the methylation level of RASSF1A gene in plasma RAS-related regions in patients with advanced lung cancer and to explore the value of RASSF1A methylation in the treatment of patients with advanced lung cancer. Methods Totally 135 venous blood samples were collected from 24 patients with advanced lung cancer before and after chemotherapy. The methylation level of RASSF1A gene was detected by fluorescence quantitative polymerase chain reaction (MSP), and the changes before and after chemotherapy were observed. Results Thirteen patients with partial remission (PR) had a significantly higher level of methylation after chemotherapy (P <0.05), while those in 11 patients with stable or stable disease (PD) There was no significant change in the methylation level of 13 patients before and after chemotherapy. Thirteen patients whose survival time was more than 12 months were also significantly increased after chemotherapy (P <0.01) No significant change in the level of change. Survival curve analysis showed that the overall survival of patients with elevated methylation level after chemotherapy was longer (P <0.01). Conclusions The detection of plasma RASSF1A methylation level in patients with advanced lung cancer before and after chemotherapy has some value in assessing the curative effect and prognosis of chemotherapy and has certain guiding significance for drug selection in personalized chemotherapy.